5 Key Takeaways

• 1

  Monitoring tumor-derived DNA in blood and urine can identify muscle-invasive bladder cancer patients likely to remain cancer-free after treatment.

• 2

  Participants achieving a complete clinical response could avoid radical cystectomy, preserving urinary function.

• 3

  Three-year bladder-intact survival for patients with complete clinical response was 69%, indicating durable bladder preservation.

• 4

  Detectable utDNA was more sensitive than ctDNA for identifying residual disease and predicting bladder-intact survival.

• 5

  The study supports integrating liquid biopsy assays into routine management of muscle-invasive bladder cancer.